◀ Back to VEGFA

PTK6 — VEGFA

Pathways - manually collected, often from reviews:

• WikiPathways Focal Adhesion: EGF/FIGF/HGF/IGF1/PDGFA/PDGFB/PGF/PDGFC/PDGFD/VEGFA/VEGFB/VEGFC → BLK/EGFR/ERBB2/FGR/FLT1/HCK/IGF1R/KDR/MET/PDGFRA/PDGFRB/PTK6/SRMS/TXK/TESK2/STYK1/TNK2/TNK1 (activation)
  

Text-mined interactions from Literome

Drevs et al., Cancer Res 2002 (Carcinoma, Renal Cell...) : PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor , affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging
Lin et al., Cancer Res 2002 (Multiple Myeloma) : Importantly, PTK787 also inhibits the increased MM cell proliferation and increased IL-6 and VEGF secretion in cultures of MM cells adherent to bone marrow stem cells
Siddiqui et al., Hematol J 2002 (Neoplasms) : We conclude that Hb-induced synthesis of VEGF in TF-bearing malignant cells is mediated by protein tyrosine kinase and by MAP-kinase pathways
Drevs et al., IDrugs 2003 : PTK/ZK , a VEGF receptor tyrosine kinase inhibitor , is under development by Novartis AG and Schering AG as an inhibitor of angiogenesis for the potential treatment of various cancers
Tsai et al., Biochem Biophys Res Commun 2003 (Glioma) : PTK inhibitors blocked glioma proliferation and epidermal growth factor (EGF) induced VEGF secretion, while H-7, a PKC inhibitor, inhibited both EGF induced and baseline VEGF secretion
Gray et al., Oncogene 2005 (Anoxia...) : In normal fibroblasts, hypoxia induced activation of the protein tyrosine kinase , Src, is required for VEGF expression
Hess-Stumpp et al., Chembiochem 2005 (Neoplasms) : PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy
Liu et al., Cancer Res 2005 (Carcinoma, Hepatocellular...) : This study examined the angiogenesis dependent and angiogenesis independent activities of PTK787/ZK222584 ( PTK787 ) , a tyrosine kinase inhibitor of VEGF receptors, in nude mice bearing human hepatocellular carcinoma xenografts
Rudin et al., NMR Biomed 2005 (Melanoma...) : PTK787/ZK222584 , a tyrosine kinase inhibitor of vascular endothelial growth factor receptor, reduces uptake of the contrast agent GdDOTA by murine orthotopic B16/BL6 melanoma tumours and inhibits their growth in vivo
Mross et al., Eur J Cancer 2005 (Liver Neoplasms...) : Phase I clinical and pharmacokinetic study of PTK/ZK , a multiple VEGF receptor inhibitor , in patients with liver metastases from solid tumours
Yazici et al., Laryngoscope 2005 (Carcinoma, Squamous Cell...) : PTK787 alone or in combination with CPT-11 reduced the phosphorylation of VEGF-R in tumor cells and tumor associated endothelial cells, was associated with decreased microvessel density, a decreased proliferative index, and an increased apoptotic index
Bian et al., Exp Eye Res 2007 : Moreover, TGF-beta2 induced RPE VEGF secretion was significantly reduced by inhibitors of mitogen activated protein ( MAP ) kinase ( MEK ) ( U0126 ), p38 ( SB202190 ), c-Jun NH2-terminal kinase (JNK), Sp600125, protein tyrosine kinase ( PTK ) ( Genistein ), and phosphatidylinositol 3-kinase (PI3K) ( Ly294002 )
Giles et al., Leuk Res 2007 (Primary Myelofibrosis) : PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor ( VEGF ), has modest activity in myelofibrosis with myeloid metaplasia
Dong et al., Biotechniques 2007 : In a proof-of-principle experiment with PTK/ZK , a small molecule inhibitor of vascular endothelial growth factor ( VEGF ) tyrosine kinase receptors, a strong correlation was observed between the decrease in bioluminescence ( 9.12-fold ) in treated mice and the actual decrease in microvessel density ( 9.16-fold ) measured after retrieval of the scaffolds and immunohistochemical staining of endothelial cells
Liu et al., Lab Invest 2009 (Disease Models, Animal...) : PTK/ZK also induced cell cycle arrest, accompanied by increasing the expression of p27 ( Kip1 ) and downregulation of cyclin D1 and cyclin E. PTK/ZK significantly inhibited vascular endothelial growth factor ( VEGF ) expression, as well as VEGF simulated cell proliferation and phosphorylation of Akt in activated HSCs
Schomber et al., Mol Cancer Ther 2009 (Disease Progression...) : In Rip1Tag2 mice, tumor angiogenesis is predominantly mediated by VEGF-A , and as expected, PTK/ZK efficiently impaired tumor blood vessel angiogenesis and tumor growth
Nijkamp et al., Ann Surg 2009 (Anoxia...) : PTK787/ZK-222584 , a nonselective Vascular Endothelial Growth Factor ( VEGF ) -receptor inhibitor , reduced RFA stimulated tumor growth and tumor growth in the RZ to a similar extent
Brandes et al., Eur J Cancer 2010 (Brain Neoplasms...) : PTK787/ZK222584 ( PTK/ZK, vatalanib ), a multiple VEGF receptor inhibitor , blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable for long-term therapy of pathologic tumour neovascularisation